The article discusses studies conducted to verify the efficacy of irinotecan-based regimens as a first-line treatment for gastric cancer. It has been stated that clinical studies conducted in Europe, the U.S. and Japan failed to propose that combination therapy with irinotecan and cisplatin (IC) is a standard treatment for the disease.